Endocyte, Inc. (ECYT)(製薬・医療分野):企業M&A動向

◆英語タイトル:Endocyte, Inc. (ECYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:GDPH137442D
◆発行会社(調査会社):GlobalData
◆発行日:2015年3月16日
◆ページ数:31
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥28,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD500 ⇒換算¥56,000見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD750 ⇒換算¥84,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary

Endocyte, Inc. (Endocyte) is a biopharmaceutical company. The company develops and markets therapies for the treatment of cancer and other inflammatory diseases. Its pipeline products include Vynfinit is used in the treatment of non-small cell lung cancer and carboplatin/paclitaxel combination phase 1; EC1456, EC1788 are used to treat Solid Tumors; Folcepri used in treatment of Folate Receptor Positive Tumors; EC1169 used to treat Prostate Cancer, EC0652 to treat Prostate Tumors; EC1669 used in the treatment of Inflammation and EC0371 for treatment of Polycystic kidney disease preclinical. Endocyte ‘s technologies include SMDC technology, companion imaging agents, and the endocyte drug development process among others. The company markets its products under the brands of Vynfinit, and Folcepri. Endocyte is headquartered in West Lafayette, Indiana, the US.

Endocyte, Inc. (ECYT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Endocyte, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Endocyte, Inc., Medical Devices Deals, 2009 to YTD 2015 9
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 10
Endocyte, Inc., Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Endocyte Secures US$8.1 Million In New Funding 11
Endocyte Secures US$26 Million In Series C-4 Round 12
Partnerships 14
Endocyte Terminates Co-Development Agreement with Merck for vintafolide 14
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 16
Licensing Agreements 18
Endocyte And Nihon Medi-Physics Enter Into Licensing Agreement For Etarfolatide 18
Endocyte Terminates Licensing Agreement With Bristol-Myers Squibb 20
Endocyte Enters Into Licensing Agreement With Purdue Research Foundation 21
Equity Offering 22
Endocyte Completes Public Offering Of Shares For US$108.7 Million 22
Endocyte Completes Underwritten Public Offering Of Common Stock For US$71.2 Million 24
Endocyte Completes IPO For US$86.3 Million 26
Endocyte, Inc. – Key Competitors 28
Key Employees 29
Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Appendix 31
Methodology 31
About GlobalData 31
Contact Us 31
Disclaimer 31

List of Tables
Endocyte, Inc., Pharmaceuticals & Healthcare, Key Facts, 2014 1
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Endocyte, Inc., Pharmaceuticals & Healthcare Deals By Type, 2009 to YTD 2015 6
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Endocyte, Inc., Deals By Therapy Area, 2009 to YTD 2015 8
Endocyte, Inc., Medical Devices Deals, 2009 to YTD 2015 9
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2009 to YTD 2015 10
Endocyte Secures US$8.1 Million In New Funding 11
Endocyte Secures US$26 Million In Series C-4 Round 12
Endocyte Terminates Co-Development Agreement with Merck for vintafolide 14
Merck Enters Into Co-Development Agreement With Endocyte For Cancer Drug 16
Endocyte And Nihon Medi-Physics Enter Into Licensing Agreement For Etarfolatide 18
Endocyte Terminates Licensing Agreement With Bristol-Myers Squibb 20
Endocyte Enters Into Licensing Agreement With Purdue Research Foundation 21
Endocyte Completes Public Offering Of Shares For US$108.7 Million 22
Endocyte Completes Underwritten Public Offering Of Common Stock For US$71.2 Million 24
Endocyte Completes IPO For US$86.3 Million 26
Endocyte, Inc., Key Competitors 28
Endocyte, Inc., Key Employees 29
Endocyte, Inc., Other Locations 30

List of Figures
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 1
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 1
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 1
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 5
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 6
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2009 to YTD 2015 7
Endocyte, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Endocyte, Inc., Medical Devices Deals, 2009 to YTD 2015 9

★海外企業調査レポート[Endocyte, Inc. (ECYT)(製薬・医療分野):企業M&A動向]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AgustaWestland N.V.:企業概要及びSWOT分析
    Product Synopsis SDI's "AgustaWestland N.V.: Aerospace and Defense - Company Profile and SWOT Report" contains in depth information and data about the company and its operations. The profile contains a company overview, key facts, major products and services, SWOT analysis, business description, com …
  • Cavotec SA:企業の戦略・SWOT・財務分析
    SummaryCavotec SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findings - D …
  • Kafr El Zayat Pesticides & Chemicals Co. (S.A.E) (KZPC):企業財務及び戦略的SWOT分析
    Summary Kafr El Zayat Pesticides & Chemicals Co. (S.A.E) (Kafr El Zayat) is a chemical company that manufactures and markets agricultural pesticides and public health products. The company’s products include foliar fertilizers, fungicides, pesticides, herbicides, public health pesticides, household …
  • Groupe Loxam:企業概要及び戦略的SWOT分析
    Groupe Loxam - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Fondation MEDINA-製薬・医療分野:企業M&A・提携分析
    Summary Fondation MEDINA (MEDINA) is a research organization that discovers biologically active molecules and drug candidates for unmet medical needs. The organization’s services include access to natural products libraries, drug discovery contract research with its high throughput screening platfor …
  • Top Glove Corp. Bhdの企業概要及び財務/SWOT分析
    Top Glove Corp. Bhd Fundamental Company Report provides a complete overview of the company’s affairs. The report includes financial and SWOT information, industry analysis, opinions, estimates, Top Glove Corp. Bhd annual and quarterly forecasts made by stock market experts. The report also enables d …
  • Population Genetics Technologies Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Population Genetics Technologies Ltd (Population Genetics) is a biotechnology company that offers diagnostic test solutions. The company provides products such as diagnostic test kits, HIV diagnostic test systems, and HCV diagnostic test systems. Its diagnostic test kits provide reagent assa …
  • WPX Energy, Inc. (WPX)(石油・ガス分野):企業M&A動向
    Summary WPX Energy, Inc. (WPX Energy) is an independent exploration and production company. The company produces natural gas, NGLs and crude oil from non-conventional resources such as tight-sands, shale formations, and coal-bed methane reserves. Its exploration assets include Powder River, San Juan …
  • Elecnor SA (ENO):企業概要、財務及び戦略的SWOT分析
    Summary Elecnor SA (Elecnor) is a provider of energy services. The company undertakes the development of projects involved in infrastructure, renewable energies and concessions, and investment businesses. It operates business in four divisions, namely, Elecnor Infrastructures, Elecnor Renewables, El …
  • Purdue Pharma L.P.:企業のM&A・提携・投資分析
    Purdue Pharma L.P. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Purdue Pharma L.P. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Hog’s Breath Cafe (Australia) Pty Ltd:企業の戦略・SWOT・財務分析
    SummaryHog's Breath Cafe (Australia) Pty Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of th …
  • Motech Industries, Inc. (6244):企業財務及び戦略的SWOT分析
    Summary Motech Industries, Inc. (Motech) is a renewable energy equipment company that develops, manufactures and markets solar products and services. The company’s products include solar cells, photovoltaic modules, photovoltaic inverter, PV power system, and photovoltaic systems, among others. It a …
  • Natrix Separations Inc:企業のM&A・提携動向(医療分野)
    Summary Natrix Separations Inc (Natrix), formerly Nysa Membrane Technologies is a medical device company that provides disposable products. The company’s products line include HD-Q membrane adsorbers and bind-elute products. Its HD-Q membrane adsorbers finds application in single-use flow-through po …
  • Vita Life Sciences Limited (VSC):企業概要、財務及び戦略的SWOT分析
    Summary Vita Life Sciences Limited (Vita Life) is a pharmaceutical company. The company provides nutritional supplements. Its products include hayfever & sinus ease, l-glutamine 750, mushroom 5 complex, probiotic + sb, quercetin complex, ultra omega 3-6-9, ultra zinc +, vitamin c 1000 plus zinc & bi …
  • Woodside Petroleum Limited:企業の戦略・SWOT・財務分析
    Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report Summary Woodside Petroleum Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Petrosibir AB (SHEL B):企業のM&A・提携動向(石油・ガス分野)
    Summary Petrosibir AB (Petrosibir), formerly Shelton Petroleum AB is an oil and gas company that offers exploration and development of oil and gas assets and the resource-rich basins in Russia and Ukraine. It holds three exploration licenses in the Russian republic of Bashkiria such as Rustamovskoye …
  • Reyes Holdings, L.L.C.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Reyes Holdings, L.L.C. Mergers …
  • GlaxoSmithKline Plc:企業のM&A・提携・投資分析
    GlaxoSmithKline Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's GlaxoSmithKline Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Alternet Systems, Inc. (ALYI):企業概要、財務及び戦略的SWOT分析
    Summary Alternet Systems, Inc. (Alternet) is a software development company. The company develops, markets and distributes internet application software and systems. It provides mobile commerce, banking and finance software solutions. Alternet offers M-Commerce, mobile transaction solutions and othe …
  • Sinovel Wind Group Co., Ltd. (601558):企業財務及び戦略的SWOT分析
    Summary Sinovel Wind Group Co., Ltd. (Sinovel) develops, designs, manufactures and commercializes the large-scale of onshore, offshore and intertidal wind turbines. It offers products such as SL1500 series wind turbine, SL2000 series wind turbine, SL3000 series wind turbine and SL6000 series wind tu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆